BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27760312)

  • 1. Impaired Mitochondrial Dynamics and Mitophagy in Neuronal Models of Tuberous Sclerosis Complex.
    Ebrahimi-Fakhari D; Saffari A; Wahlster L; Di Nardo A; Turner D; Lewis TL; Conrad C; Rothberg JM; Lipton JO; Kölker S; Hoffmann GF; Han MJ; Polleux F; Sahin M
    Cell Rep; 2016 Oct; 17(4):1053-1070. PubMed ID: 27760312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using tuberous sclerosis complex to understand the impact of MTORC1 signaling on mitochondrial dynamics and mitophagy in neurons.
    Ebrahimi-Fakhari D; Saffari A; Wahlster L; Sahin M
    Autophagy; 2017 Apr; 13(4):754-756. PubMed ID: 28121223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
    Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
    Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
    Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
    J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of TSC1 and TSC2 proteins in neuronal axons.
    Karalis V; Wood D; Teaney NA; Sahin M
    Mol Psychiatry; 2024 Apr; 29(4):1165-1178. PubMed ID: 38212374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions.
    Magri L; Cambiaghi M; Cominelli M; Alfaro-Cervello C; Cursi M; Pala M; Bulfone A; Garcìa-Verdugo JM; Leocani L; Minicucci F; Poliani PL; Galli R
    Cell Stem Cell; 2011 Nov; 9(5):447-62. PubMed ID: 22056141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells.
    Magini A; Polchi A; Di Meo D; Mariucci G; Sagini K; De Marco F; Cassano T; Giovagnoli S; Dolcetta D; Emiliani C
    Hum Mol Genet; 2017 Sep; 26(17):3303-3312. PubMed ID: 28637240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin and tuberous sclerosis complex.
    Wataya-Kaneda M
    J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.
    Medvetz D; Priolo C; Henske EP
    Mol Cancer Res; 2015 Jan; 13(1):3-8. PubMed ID: 25298408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
    Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
    eNeuro; 2015; 2(6):. PubMed ID: 26693177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
    Pal R; Xiong Y; Sardiello M
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
    Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
    J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.
    Taneike M; Nishida K; Omiya S; Zarrinpashneh E; Misaka T; Kitazume-Taneike R; Austin R; Takaoka M; Yamaguchi O; Gambello MJ; Shah AM; Otsu K
    PLoS One; 2016; 11(3):e0152628. PubMed ID: 27023784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberous sclerosis--A model for tumour growth.
    Dodd KM; Dunlop EA
    Semin Cell Dev Biol; 2016 Apr; 52():3-11. PubMed ID: 26816112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
    Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
    J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex.
    Karalis V; Caval-Holme F; Bateup HS
    Nat Commun; 2022 Aug; 13(1):4665. PubMed ID: 35945201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSC but not PTEN loss in starving cones of retinitis pigmentosa mice leads to an autophagy defect and mTORC1 dissociation from the lysosome.
    Venkatesh A; Ma S; Punzo C
    Cell Death Dis; 2016 Jun; 7(6):e2279. PubMed ID: 27362797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis.
    Costa V; Aigner S; Vukcevic M; Sauter E; Behr K; Ebeling M; Dunkley T; Friedlein A; Zoffmann S; Meyer CA; Knoflach F; Lugert S; Patsch C; Fjeldskaar F; Chicha-Gaudimier L; Kiialainen A; Piraino P; Bedoucha M; Graf M; Jessberger S; Ghosh A; Bischofberger J; Jagasia R
    Cell Rep; 2016 Apr; 15(1):86-95. PubMed ID: 27052171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.
    Lam HC; Baglini CV; Lope AL; Parkhitko AA; Liu HJ; Alesi N; Malinowska IA; Ebrahimi-Fakhari D; Saffari A; Yu JJ; Pereira A; Khabibullin D; Ogorek B; Nijmeh J; Kavanagh T; Handen A; Chan SY; Asara JM; Oldham WM; Diaz-Meco MT; Moscat J; Sahin M; Priolo C; Henske EP
    Cancer Res; 2017 Jun; 77(12):3255-3267. PubMed ID: 28512249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
    Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
    Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.